CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
Volume 15 Issue 2

Advancements of Gene Editing Technologies(CRISPR/Cas9)

An Introduction to Gene Editing – CRISPR-Cas9 The dynamic promise of gene editing for humans is the ability to precisely manipulate the sequence of the cell genom...
Continue Reading →
News

Horizon Discovery enters into agreement with Roche Diagnostics to support the development of immunohistochemistry assays for oncology

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into an agreement with Roche Diagn...
Continue Reading →
News

Sphere Fluidics and Geneva Biotech receive Eurostars genome editing grant

Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, and Geneva Biotech, an EMBL spin-out devel...
Continue Reading →
News

Locus Biosciences raises $19 million series A for CRISPR-Cas3 Antimicrobials

Locus Biosciences has closed $19 million in Series A funding led by venture capital firm ARTIS Ventures with additional financing from notable institutional investor...
Continue Reading →
News

IDT Provides Optimized Conditions for HDR in CRISPR Editing

As an advocate for the genomics age, Integrated DNA Technologies (IDT), has published a new application note on optimization of CRISPR-Cas9 for homology-directed rep...
Continue Reading →
News

Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPR...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026